Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8436581 | 1.00 | HCAR2 (0.52) | HCAR2KMT2AMAPTLMNANPSR1 | |
| SCHEMBL8303644 | 0.80 | HCAR2 (0.55) | HCAR2KMT2AMAPTLMNANPSR1 | |
| SCHEMBL11539420 | 0.80 | HCAR2 (0.55) | HCAR2KMT2AMAPTLMNANPSR1 | |
| SCHEMBL8303646 | 0.80 | HCAR2 (0.55) | HCAR2KMT2AMAPTLMNANPSR1 | |
| SCHEMBL1930557 | 0.77 | AKR1C3 (0.52) | HCAR2KMT2AMAPTLMNANPSR1 | |
| SCHEMBL9709967 | 0.77 | HCAR2 (0.52) | HCAR2KMT2AMAPTLMNANPSR1 | |
| SCHEMBL9709963 | 0.77 | HCAR2 (0.52) | HCAR2KMT2AMAPTLMNANPSR1 | |
| SCHEMBL8182843 | 0.77 | AKR1C3 (0.52) | HCAR2KMT2AMAPTLMNANPSR1 | |
| SCHEMBL9709969 | 0.77 | HCAR2 (0.52) | HCAR2KMT2AMAPTLMNANPSR1 | |
| SCHEMBL11074309 | 0.76 | HCAR2 (0.50) | HCAR2KMT2AMAPTLMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4169149-A | Use of α-mercapto-β-arylacrylic acid derivatives in heavy metal poisoning | GIROUX EUGENE L | 1979-09-25 | — | — | US | claimed |
| US-4130653-A | 2-MERCAPTO-3-ARYL ACRYLIC ACID | MERRELL TORAUDE ET COMPAGNIE (FR) | 1978-12-19 | — | — | US | claimed |
| US-4124718-A | ADMINISTERING A-MERCAPTO-B-ARYL-ACRYLIC ACIDS | MERRELL TORAUDE ET COMPAGNIE (FR) | 1978-11-07 | — | — | US | claimed |
| US-20140087003-A1 | METHOD FOR TREATING VENOMOUS BITES AND STINGS | CISNEROS IGNACIO (US) | 2014-03-27 | — | — | US | disclosed |
| US-5929249-A | ANGIOTENSIN II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-07-27 | — | — | US | disclosed |
| US-5728842-A | ANGIOTENSIN II RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM CORPORATION (US) | 1998-03-17 | — | — | US | disclosed |
| EP-0653937-A4 | CHEMICAL COMPOUNDS. | SMITHKLINE BEECHAM CORP (US) | 1996-07-31 | — | — | EP | disclosed |
| EP-0653937-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1995-05-24 | — | — | EP | disclosed |
| WO-1994000120-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-01-06 | — | — | WO | disclosed |
| US-4439443-A | REDUCE HEMORRHAGE WITH MERCAPTO THIENYL ACRYLIC ACIDS OR DISULFIDES | RICHARDSON-MERRELL INC. (US) | 1984-03-27 | — | — | US | disclosed |
| US-4347255-A | REDUCING HEMORRHAGE AND NECROSIS WITH ALPHA-MERCAPTO-BETA-HETERO ACRYLIC ACIDS AND DISULFIDES | RICHARDSON-MERRELL INC. (US) | 1982-08-31 | — | — | US | disclosed |
| US-4226882-A | Use of α,α'-dithiobis-(β-arylacrylic acid) derivatives in the treatment of hypertension | MERRELL TORAUDE ET COMPAGNIE (FR) | 1980-10-07 | — | — | US | disclosed |
| US-4210664-A | Use of α,α'-dithiobis(β-arylacrylic acid) derivatives to enhance zinc serum and tissue concentrations | MERRELL TORAUDE ET COMPAGNIE (FR) | 1980-07-01 | — | — | US | disclosed |
| US-4210665-A | Use of α,α'-dithiobis(β-arylacrylic acid) derivatives in heavy metal poisoning | MERRELL TORAUDE ET COMPAGNIE (FR) | 1980-07-01 | — | — | US | disclosed |
| US-4169149-A | Use of α-mercapto-β-arylacrylic acid derivatives in heavy metal poisoning | GIROUX EUGENE L | 1979-09-25 | — | — | US | disclosed |
| US-4130653-A | 2-MERCAPTO-3-ARYL ACRYLIC ACID | MERRELL TORAUDE ET COMPAGNIE (FR) | 1978-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140087003-A1 | METHOD FOR TREATING VENOMOUS BITES AND STINGS | STING1, CPA3, GZMB | HCAR2 2487/4885KMT2A 2091/4885MAPT 2913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.